Delivery Order SPE2DB20D9226-SPE2DB25FQ62E
Award Date
6/12/25
Potential Completion Date
7/7/25
Potential Value
$8.3K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The $3,471.55 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of July 1, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The award has a ceiling value of $8,576.28 and is a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to support the recurring medical needs...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $6,248.79 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, with a period of performance through June 17, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, which enables the agency to issue delivery orders for a...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The contract is a $6,943.10 firm fixed-price delivery order for the supply of 4,568,023,201 units of NEXPLANON 68 MG IMPLANTS, a contraceptive device. The contract has an ultimate completion date of May 14, 2025 and was awarded on April 23, 2025. DMS Pharmaceutical Group holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth up to $8,576.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, with a ceiling value of $7,146.90 and a period of performance through September 27, 2024. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Nexplanon 68 mg implants. The contract, valued at $6,943.10, has an ultimate completion date of May 12, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business (WOSB) pharmaceutical wholesaler, provides NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA). The $7,146.90 firm fixed-price delivery order contract has an ultimate completion date of August 21, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) for the delivery of Nexplanon 68 mg implants. The fixed-price delivery order, valued at $10,414.65, has a performance period ending on May 9, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a wide range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA) under the Medical Supply Chain program. The firm fixed-price delivery order, valued at $7,146.90, has an ultimate completion date of September 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications, including branded and generic...